Pfizer Inc. $PFE Shares Bought by Integrity Alliance LLC.

Integrity Alliance LLC. boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 24.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 113,598 shares of the biopharmaceutical company’s stock after acquiring an additional 22,457 shares during the quarter. Integrity Alliance LLC.’s holdings in Pfizer were worth $2,829,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Horizon Financial Services LLC lifted its holdings in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the period. YANKCOM Partnership acquired a new position in shares of Pfizer in the 4th quarter valued at about $28,000. HFM Investment Advisors LLC lifted its holdings in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the period. Darwin Wealth Management LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at about $32,000. Finally, Torren Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced new late-stage trial activity for its infant pneumococcal vaccine and obesity drug berobenatide, reinforcing that the company is pushing to build future growth drivers beyond its aging portfolio. Pfizer’s Next-Gen Infant Pneumococcal Vaccine Trial: What Investors Should Watch Now
• Positive Sentiment: BofA Securities raised its price target on Pfizer to $27 from $26 after strong first-quarter results and improved 2026 revenue/EPS estimates, signaling continued analyst confidence in the stock’s valuation. BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results
• Positive Sentiment: Pfizer is also highlighting its obesity push with a new Phase 3 trial, which could add another major opportunity if results are favorable. Pfizer Steps Up Obesity Push With New Phase 3 Berobenatide Trial
• Neutral Sentiment: Recent commentary says Pfizer is leaning on new launches, Seagen assets, and pipeline progress to offset looming loss-of-exclusivity pressure, but the patent cliff through 2030 remains a major overhang for investors. Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?
• Negative Sentiment: Broader industry coverage on the Eliquis patent cliff underscores the kind of revenue loss Pfizer and peers can face when exclusivity ends, keeping attention on the company’s future replacement pipeline. Thinning revenues: inside the $14bn Eliquis patent cliff

Pfizer Price Performance

Shares of Pfizer stock opened at $26.24 on Thursday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.06 and a twelve month high of $28.75. The business has a 50-day moving average price of $26.82 and a 200 day moving average price of $26.27. The firm has a market cap of $149.55 billion, a PE ratio of 20.03 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the previous year, the business earned $0.92 EPS. Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s payout ratio is 131.30%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. Guggenheim boosted their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. HSBC boosted their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.61.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.